June 10, 2020Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients Read more »
July 31, 2020Economic burden of checkpoint inhibitor immunotherapy for the treatment of non-small cell lung cancer in U.S. clinical practice Read more »
November 1, 2019Unique tumor immune microenvironments of potentially PD-L1/TGF-β trap responsive tumors Read more »
December 2, 2020Complex markers of survival from pembrolizumab: The potential predictive role of tumor mutational burden (TMB) and KRAS Read more »
May 15, 2023Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay Read more »
December 1, 2020PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer Read more »
January 9, 2020TCR convergence in individuals treated with immune checkpoint inhibition for cancer Read more »
